Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Metastatic Castration-resistant Prostate Cancer Clinical Trials

10 recruiting trials for Metastatic Castration-resistant Prostate Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
3
Phase 3 Trials
9
Sponsors

Recruiting Trials

RECRUITINGNCT05116579

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

To evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment

Sponsor: Sun Yat-sen UniversityEnrolling: 301 location
RECRUITINGPhase 2NCT04986423

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior...

Sponsor: Zenith EpigeneticsEnrolling: 20020 locations
RECRUITINGNCT06529549

Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed...

This observational study aims to learn about the effects and safety of organoid-based drug sensitivity screening in mCRPC patients with bone metastases that progressed after...

Sponsor: Sun Yat-sen UniversityEnrolling: 301 location
RECRUITINGPhase 1NCT07339267

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT). Prednisone is a...

Sponsor: Astellas Pharma Global Development, Inc.Enrolling: 121 location
RECRUITINGPhase 2NCT06971211

Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC

This study is an open label, single arm, multicenter clinical trial. The aim of this study is to evaluate the efficacy, safety, and quality of life of radiotherapy combined with...

Sponsor: Jianbin BiEnrolling: 401 location
RECRUITINGPhase 3NCT06629779

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC...

Sponsor: PfizerEnrolling: 90020 locations
RECRUITINGPhase 3NCT07213674

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic...

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel,...

Sponsor: AmgenEnrolling: 75020 locations
RECRUITINGPhase 1NCT06895811

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

This is a single-arm, single-center, open-label clinical trial designed to evaluate the clinical safety and tolerability of different doses of Prostate-Specific Membrane Antigen...

Sponsor: Shanghai Changzheng HospitalEnrolling: 31 location
RECRUITINGPhase 1 / Phase 2NCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients...

Sponsor: Novartis PharmaceuticalsEnrolling: 27520 locations
RECRUITINGPhase 3NCT06764485

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants...

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant...

Sponsor: CelgeneEnrolling: 96020 locations